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Abstract
Background: Pharmacopuncture is a relatively new acupuncture therapy combining acupuncture with herbal
medicine. While pharmacopuncture is applied extensively in Korean medicine treatment, there are no clinical
reports regarding what types of pharmacopuncture are used for which diseases.
Methods: Data was extracted retrospectively from the electronic medical records of all inpatients and outpatients
at 12 Korean medicine hospitals and clinics during the period of December 17, 2010 to October 2, 2014. Treatment
patterns for acupuncture, electroacupuncture and pharmacopuncture were analyzed. Principle diagnosis codes,
frequency of treatment, pharmacopuncture type and costs were investigated to assess pharmacopuncture use in
clinical settings.
Results: During the study period, a total 33,415 inpatients and 373,755 outpatients visited the study sites, and most
were musculoskeletal. Among inpatients and outpatients, 98.6 % and 77.6 % received pharmacopuncture, respectively.
Administration rate of pharmacopuncture for the 10 most frequent principle diagnosis codes was 97.2–99.3 % in
inpatients, and that for outpatients was 73.0–91.5 %. The average number of pharmacopuncture sessions in
pharmacopuncture recipients was 8.2 ± 12.3 for outpatients and 25.8 ± 18.7 for inpatients. The mean total cost for
pharmacopuncture per patient was $556.24 ± 174.62 among inpatients, and $149.16 ± 243.85 among outpatients.
Estimated average cost per pharmacopuncture session was $23–24 for inpatients, and $17–18 for outpatients.
Shinbaro1, bee venom, Hwangryunhaedok, and Shinbaro2 were the most frequently used pharmacopuncture types.
Conclusions: This is the first analysis of treatment patterns of pharmacopuncture in a large-scale Korean medicine
hospital/clinic patient population. We verified patterns of pharmacopuncture use for musculoskeletal disease treatment
in Korea, and use of pharmacopuncture varied depending on disease or symptom severity. These results are expected
to contribute to future clinical study design and standardization of pharmacopuncture.
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Background
Acupuncture is a treatment procedure where needles are
inserted at acupoints through the skin, and has been
used mainly in and around East Asia with a history of at
least 2000 years. Based on its long history and wide-
spread use of CAM throughout the world, various new
acupuncture techniques are being developed. One such
relatively new acupuncture technique is pharmacopunc-
ture (or herbal acupuncture) which combines acupunc-
ture and herbal medicine by injecting herbal extracts
into acupoints. Early forms of pharmacopuncture started
in China in the early 1950s and were referred to as acu-
point injection or aqua-puncture [1, 2]. Pharmacopunc-
ture was later introduced to Korea and adopted by
Korean medicine doctors through Nam in the 1960s [3].
Use is considered to have become widespread since the
1990s, and the fast-paced growth of pharmacopuncture
is generally attributed to clinical observation of its effect-
iveness and experimental evidence of efficacy for various
conditions [4]. While pharmacopuncture has extended
use to various diseases in Korea, there are no clinical re-
ports regarding how much of which types of pharmaco-
puncture are used at what cost, or for which diseases.
Official insurance claims statistics for pharmacopuncture
are only available for automobile insurance coverage,
and it was reported that approximately 1,555,000 phar-
macopuncture sessions were administered to 168,089
patients for related treatments in 2014 [5]. Though these
numbers suggest that pharmacopuncture is applied ex-
tensively in clinical practice, it is difficult to establish
specific indications for pharmacopuncture use as costs
are mainly paid out-of-pocket. The major applications of
pharmacopuncture can be inferred from previous stud-
ies, and Kim et al. [4] reported in a descriptive analysis
of pharmacopuncture studies in Korea that it was used
for a wide range of diseases, from lumbar, immune sys-
tem and gynecological disorders to cancer-related dis-
eases. Also, a 2011 meta-analysis was conducted on the
effect of pharmacopuncture in asthma [6]. While a study
of pharmacopuncture-related RCTs published in relevant
academic journals in Korea similarly reported that phar-
macopuncture was applied to various diseases including
functional headache and dysmenorrhea, the majority of
clinical studies concerned musculoskeletal disorders [7].
This is consistent with reports that Korean medicine
(KM) is used most commonly for musculoskeletal disor-
ders in Korea [8], and pharmacopuncture is also consid-
ered to be used mainly for musculoskeletal disorders in
light of previous reports on the effect of pharmacopunc-
ture for such disorders as lumbar intervertebral disc dis-
placement (IDD) [9], degenerative knee osteoarthritis
[10], and ankle sprain [11]. Moreover, according to a re-
cent survey on practice patterns of IDD treatment,
95.9 % of responding Korean medicine doctors (KMDs)
replied that they incorporated pharmacopuncture in their
practice for lumbar IDD, suggesting that pharmacopunc-
ture is commonly used for IDD [12]. A clinical guideline
developed in Korea also recommends bee venom, Soyeom
(消炎), Joongseongouhyul (中性瘀血), and Shinbaro phar-
macopuncture for IDD at recommendation level B [13].
Although it can be surmised that pharmacopuncture is a
regular part of KM practice, currently reports on clinical
practice patterns are scarce. Although the abovementioned
survey on IDD was an investigation on pharmacopuncture
use [12], usage amounts were estimates based on KMD
opinion and not supported by concrete data sources such
as medical records. Due to paucity of investigations on
pharmacopuncture type, application, duration, and dosage,
there is increased difficulty in standardization of pharma-
copuncture administration method and development of
clinical practice guidelines. More consideration should be
given to wider insurance coverage of pharmacopuncture
to reduce financial burden, but lack of data on clinical ap-
plication is an obstacle to health insurance inclusion, po-
tentially leading to increase in health-related costs. KM
has yet to establish standardized pharmacopuncture guide-
lines by disease, and this study therefore attempted to
comprehensively evaluate clinical trends of pharmaco-
puncture use in musculoskeletal disorders. The study out-
comes are expected to contribute as basic information to
determining health insurance coverage for pharmacopunc-
ture and standardization of pharmacopuncture.
Methods
Data was extracted retrospectively from all inpatient and
outpatient electronic medical records (EMRs) at 12 sites of
KM hospitals and clinics from December 17, 2010 to
October 2, 2014 including basic patient characteristics (sex,
age), outpatient visit information (treatment duration, num-
ber of visits, principle diagnosis code, and treatment con-
tents regarding acupuncture, electroacupuncture, and
pharmacopuncture), and hospitalization information (dur-
ation of hospital stay, number of admissions, and treatment
contents regarding acupuncture, electroacupuncture, and
pharmacopuncture). Study sites were sampled from 12 KM
hospitals and clinics covering 5 districts including Seoul
(Gangnam, Nowon, Mok-dong, Yeongdeungpo and Jamsil),
Daejeon, Busan (Haeundae), Changwon and Gyeonggi
(Bucheon, Bundang, Suwon and Ansan), in order to gain
insight to nationwide trends by securing a maximum
number of sites. Considering for potential difference in pre-
scription trends by visit type, subjects were analyzed as in-
patients and outpatients, and principle diagnosis codes,
number of treatment sessions, and costs were investigated
to assess use of pharmacopuncture in clinical settings. Dis-
ease information conformed to EMR principle diagnosis
codes following the Korean Standard Classification of Dis-
eases (KCD), which corresponds to the 10th revision of the
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International Standard Classification of Diseases (ICD-10),
and in absence of principle diagnosis code, diagnosis code
of highest frequency served as the principle diagnosis code
in analysis. Number of outpatient visits was tallied as num-
ber of visits during the treatment period, hospital stay dur-
ation was defined as total number of days from date of
admission to discharge, admission number as total number
of admissions, and sessions of acupuncture and pharmaco-
puncture was totaled as the number of prescriptions during
hospital visits or stay. Many different prescription codes
refer to pharmacopuncture treatment procedures, and for
this reason KMDs in clinical practice classified prescription
code names by pharmacopuncture type prior to analysis.
As multiple pharmacopuncture types may be used in an in-
dividual patient for different symptoms, pharmacopuncture
frequency was analyzed from total pharmacopuncture
treatment prescriptions per patient. Some patients were in-
cluded in both the inpatient and outpatient groups as it
was common for discharged inpatients to continue treat-
ment as outpatients. The authors attempted to reduce bias
by mutually exclusively analyzing all acupuncture and phar-
macopuncture prescriptions during hospital stay as in-
patient cases, and all during outpatient visits as outpatient
cases. Included participants were covered by a variety of in-
surances including national health insurance, medicaid, and
automobile insurance, and all patient data was included for
analysis regardless of insurance type. In cost analysis, how-
ever, while acupuncture and electroacupuncture have fixed
costs as reimbursement items in Korea, pharmacopuncture
costs are either paid entirely out of pocket or covered by
automobile insurance. For this reason, pharmacopuncture
treatment codes for automobile insurance coverage were
excluded from cost analysis. All costs are presented as U.S.
dollars at the exchange rate as of December 2015 (1175.50
Korean won = 1 U.S. dollar).
Results
Participants
A total 33,415 inpatients and 373,755 outpatients were
included as study subjects from December 17, 2010 to
October 2, 2014. Among inpatients, 15,043 (45 %) were
male and 18,372 (55 %) female, and among outpatients,
47.7 % were male and 52.3 % female. Average age of in-
patients was 45.6 ± 14.0 years, slightly older than the
43.9 ± 15.4 years of the outpatient group. Average length
of hospital stay was 19.0 ± 12.5 days, and the average
number of admissions in inpatients was 1.3 ± 0.8 times.
In outpatients, the average number of visits was 7.5 ±
11.9 times (Table 1).
Frequency of acupuncture, electroacupuncture, and
pharmacopuncture treatment
Of 33,415 inpatients, 32,947 patients received 1 or more
sessions of pharmacopuncture, which correlated to 98.6 %
of total inpatients. A total 99.4 % of inpatients were ad-
ministered acupuncture, 85.9 % electroacupuncture, and
98.6 % pharmacopuncture, showing that almost all inpa-
tients received both acupuncture and pharmacopuncture.
Average number of pharmacopuncture treatment sessions
during hospital stay was 22.8 ± 18.4 times, and the median
was 19 times, indicating that though most patients under-
went pharmacopuncture treatment once a day, some re-
ceived pharmacopuncture twice or more a day considering
that average hospital stay was 19.0 ± 12.5 days.
Among 373,755 outpatients, 85.3 % received acupunc-
ture, 72.8 % electroacupuncture, and 77.6 % pharmaco-
puncture. In recipients of pharmacopuncture, the average
number of pharmacopuncture treatment sessions was 8.2
± 12.3 times (median 3). While frequency of acupuncture
was comparable to that of pharmacopuncture in the in-
patient group, it was higher than that of pharmacopunc-
ture in outpatients (Table 2).
Number of pharmacopuncture sessions by major disease
and principle diagnosis code
The 10 most frequent principle diagnosis codes among
inpatients were M51, S33, M54, M50, S13, M48, M17,
M47, S83, and M25, in order of frequency, and a total
88.5 % of inpatients fell under these principle diagnosis
code categories. The 10 most frequent principle diagno-
sis codes in outpatients were S33, M51, M54, S13, M50,
S93, S83, M25, S43, and M48, in order of frequency, di-
verging from the order presented in the inpatient group.
In outpatients, principle diagnosis codes involving joint
disorders such as shoulder and ankle joint were more
common. In addition, 81.4 % of outpatients were cov-
ered by these 10 principle diagnosis codes, suggesting
that the ambulatory department displayed wider range
in diagnosis code. The proportion of patients receiving
acupuncture and pharmacopuncture, respectively, were
highly similar for each principle diagnosis code in inpa-
tients, and proportion for pharmacopuncture was
slightly lower for S13 and S83 compared to other diag-
nosis codes. However, the proportion of patients receiv-
ing acupuncture was over 10%p different from that of
pharmacopuncture for S33, S13, S93, S83, and S43,






Male (n, (%)) 15,043 (45) 178,384 (47.7)
Female (n, (%)) 18,372 (55) 195,371 (52.3)
Age (mean ± SD, years) 45.6 ± 14.0 43.9 ± 15.4
Number of treatments 1.3 ± 0.8 7.5 ± 11.9
Treatment duration (mean ± SD, days)a 19.0 ± 12.5
aTreatment duration in the ambulatory department is not shown as the
calculation method is likely to overestimate duration
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compared to small difference in M51, suggesting that
pharmacopuncture use is determined by severity or dur-
ation of disease (Table 3).
Types of pharmacopuncture
The most commonly used types of pharmacopuncture
among inpatients were Shinbaro1, Hwangryunhaedok,
bee venom, Shinbaro2, and Joongseongouhyul in order
of frequency, and in outpatients, Shinbaro1, bee venom,
Hwangryunhaedok, Shinbaro2, and Joongseongouhyul
were used most frequently in this order (Table 4). The
preparation method for each pharmacopuncture type is
shown in Table 5. All pharmacopuncture solutions were
prepared in cleanrooms at Jaseng herbal dispensary, an
extramural facility adhering to Korean Good Manufac-
turing Practice (K-GMP) standards.
Pharmacopuncture-related costs
As pharmacopuncture cost differs by insurance, this
study chose to exclude patients receiving pharmaco-
puncture treatment under automobile insurance cover-
age, and accordingly analyzed pharmacopuncture costs
in 32,246 inpatients and 229,219 outpatients. Pharmaco-
puncture costs for the entire duration of treatment for
each patient were totaled, and the average total cost filed
in insurance claims was $556.24 ± 174.62 per patient in
inpatients, and $149.16 ± 243.85 in outpatients.
Discussion
Pharmacopuncture is a relatively new acupuncture format
that embodies aspects of both manual acupuncture and
herbal medicine by injecting purified herbal extracts ac-
cording to herbal medicine properties and flavors at acu-
points relevant to the disease. Its efficacy is considered to
Table 2 Frequency of acupuncture, electroacupuncture, and pharmacopuncture
Inpatient (n = 33,415) Outpatient (n = 373,755)
Acupuncture n (%) 33,198 (99.4 %) 318,764 (85.3 %)
sessions (mean ± SD) 25.8 ± 18.7 8.0 ± 12.2
median (quantile) 22 (11, 37) 3 (1, 10)
Electroacupuncture n (%) 28,703 (85.9 %) 272,033 (72.8 %)
sessions (mean ± SD) 15.4 ± 13.0 7.9 ± 11.9
median (quantile) 12 (6, 21) 3 (1, 10)
Pharmacopuncture n (%) 32,947 (98.6 %) 289,860 (77.6 %)
sessions (mean ± SD) 22.8 ± 18.4 8.2 ± 12.3
median (quantile) 19 (9, 31) 3 (1, 10)
Table 3 Acupuncture and pharmacopuncture usage by principle diagnosis code
Principle
diagnosis code











Total 33,415 33,198 32,947 Total 373,755 318,764 289,860
M51 12,597 (37.7) 12,547 (99.6) 12,495 (99.2) S33 94,536 (25.3) 88,234 (93.3) 78,639 (83.2)
S33 7774 (23.3) 7726 (99.4) 7662 (98.6) M51 61,844 (16.5) 57,275 (92.6) 56,062 (90.7)
M54 2708 (8.1) 2684 (99.1) 2657 (98.1) M54 61,213 (16.4) 53,203 (86.9) 49,371 (80.7)
M50 2475 (7.4) 2461, (99.4) 2451 (99.0) S13 31,057 (8.3) 31,057 (93.5) 25,530 (82.2)
S13 1307 (3.9) 1297 (99.2) 1271 (97.2) M50 18,589 (5.0) 18,589 (93.5) 17,007 (91.5)
M48 695 (2.1) 692 (99.6) 690 (99.3) S93 9159 (2.5) 9159 (93.0) 6682 (73.0)
M17 561 (1.7) 557 (99.3) 553 (98.6) S83 7762 (2.1) 7762 (90.9) 4074 (80.7)
M47 539 (1.6) 536 (99.4) 531 (98.5) M25 7182 (1.9) 7182 (89.6) 3065 (81.4)
S83 461 (1.4) 455 (98.7) 450 (97.6) S43 6710 (1.8) 6710 (92.1) 6263 (82.2)
M25 433 (1.3) 431 (99.5) 430 (99.3) M48 5871 (1.6) 5871 (91.5) 5843 (88.2)
M51: Other intervertebral disc disorders, S33: Dislocation, sprain and strain of joints and ligaments of lumbar spine and pelvis, M54: Dorsalgia, S13: Dislocation,
sprain and strain of joints and ligaments at neck level, M48: Other spondylopathies, M17: Gonarthorosis [arthrosis of knee], M47: Spondylosis, S83: Dislocation,
sprain and strain of joints and ligaments of knee, M25: Other joint disorders, NEC, S93: Dislocation, sprain and strain of joints and ligaments at ankle and foot
level, S43: Dislocation, sprain and strain of joints and ligaments of shoulder girdle
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take synergistic effect by implementing and combining the
physical effect of acupoint stimulation and the chemical
effect of herbal extracts. There are reports that pharmaco-
puncture heightens the clinical effect of acupuncture
when combined with acupuncture compared to acupunc-
ture alone, and pharmacopuncture is drawing attention as
a possible solution for various refractory diseases [14].
While it can be conjectured that pharmacopuncture usage
is high for various diseases from an overview of pharma-
copuncture studies conducted in Korea, there are no re-
ports providing clinical information as to which types of
pharmacopuncture are used at which acupoints for what
diseases. Analysis of previous clinical studies on pharma-
copuncture shows that per acupoint and total pharmaco-
puncture volume are highly variable from 0.01 to 0.5 cc
with one study reporting injection of 3.5 cc intra-
articularly, and from 0.01 to 1.5 cc, respectively [15].
Meanwhile, a recent survey on pharmacopuncture use for
IDD in KMDs reported ranges between 1.3 and 3.5 cc,
likewise displaying a wide range [12]. While these figures
may be a reflection of differences in disease, patient symp-
toms or severity, it may also be taken as an indication of
absence of a standardized procedure. Moreover, previous
studies are highly heterogeneous with regard to interven-
tion with pharmacopuncture agents ranging from single
solution ingredients such as hominis placenta and bee
venom, to herbal mixtures such as Hwangryunhaedok and
Joongseongouhyul, and preparation methods were likewise
diverse [15]. Taking these circumstances into account,
standardization of pharmacopuncture solution preparation
methods and establishment of standard pharmacopuncture
procedures by disease would seem to deserve high priority,
and efforts are steadily being put toward standardization
and improvement of pharmacopuncture efficacy and stabil-
ity [16–19]. The multiform methods of administration are
an added difficulty to standardization and potential
Table 4 Most frequently used pharmacopuncture types
Pharmacopuncture in inpatient care n (%) Pharmacopuncture in outpatient care n (%)
Total 32,947 (100) Total 289,860 (100)
Shinbaro 1 17,733 (53.8) Shinbaro 1 80,893 (27.9)
Hwangryunhaedok (黃蓮解毒) 11,596 (35.2) Bee venom 49,279 (17.0)
Bee venom 10,560 (32.1) Hwangryunhaedok (黃蓮解毒) 42,173 (14.5)
Shinbaro2 4622 (14.0) Shinbaro2 25,188 (8.7)
Joongseongouhyul (中性瘀血) 2001 (6.1) Joongseongouhyul (中性瘀血) 19,418 (6.7)
Hominis placenta (紫河車) 1233 (3.7) Hominis placenta (紫河車) 8788 (3.0)
Shinbaro 3 1137 (3.5) Muscle relaxation 4585 (1.6)
Muscle relaxation 358 (1.1) Shinbaro3 4550 (1.6)
Table 5 Preparation of frequently used pharmacopuncture solutions
Preparation methods
Shinbaro 1 Herbal extraction (Cibotium barometz, Saposhnikovia divaricata, Eucommia ulmoides, Acanthopanax sessiliflorus,
Ostericum koreanum, Angelica pubescens, Achyranthes japonica, Paeonia lactiflora) using reflux extraction with
70 % spiritus vinosus→ progressive purification using alcohol immersion→ freeze-drying→ dilution
→ filtering→ sterilization
Shinbaro 2 Herbal extraction (Cibotium barometz, Saposhnikovia divaricata, Eucommia ulmoides, Acanthopanax
sessiliflorus, Ostericum koreanum, Angelica pubescens, Achyranthes japonica, Paeonia albiflora, Scolopendra
subspinipes) using reflux extraction with 70 % spiritus vinosus→ progressive purification using alcohol
immersion→ freeze-drying→ dilution→ filtering→ sterilization
Shinbaro 3 Herbal extraction (Harpagophytum procumbens) extraction using reflux extraction with 70 % spiritus vinosus
→ progressive purification using alcohol immersion→ freeze-drying→ dilution→ filtering→ sterilization
Bee venom Purification of dried bee venom→ freeze-drying→ dilution→ filtering
Hwangryunhaedok (黃蓮解毒) Herbal distillation extraction (Coptis japonica, Scutellaria baicalensis, Phellodendron amurense, Gardenia
jasminoides)→ filtering→ sterilization
Joongseongouhyul (中性瘀血) Herbal distillation extraction (Gardenia jasminoides, Commiphora molmol, Boswellia carterii, Corydalis ternate,
Paeonia obovata, Salvia miltiorrhiza, Caesalpina sappan)→ filtering→ sterilization
Hominis placenta (紫河車) Hominis placenta extracts approved for herbal medicine preparation→ filtering→ sterilization
Muscle relaxation Herbal extraction (Paeonia lactiflora, Glycyrrhiza uralensis) using reflux extraction with 70 % spiritus
vinosus→ progressive purification using alcohol immersion→ freeze-drying→ dilution→ filtering→ sterilization
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inclusion of pharmacopuncture in national insurance
coverage. While standardization of administration proced-
ure by disease in addition to solution preparation is a press-
ing matter, the exact amount of pharmacopuncture used in
clinical settings is yet unclear due to noncoverage. The
study sites included KM hospitals specializing in spine dis-
orders designated as such by the Korean Ministry of Health
and Welfare, and all study sites were KM hospitals and
clinics that treated a large number of musculoskeletal pa-
tients on a regular basis. A 2009 review of Korean RCTs on
pharmacopuncture showed that studies on patients with
musculoskeletal disorders such as degenerative knee osteo-
arthritis, low back and/or leg pain, shoulder and/or arm
pain, and ankle sprain were most frequent [7], and taking
into account that Korean medicine is mainly used for mus-
culoskeletal disorders in Korea, these KM hospitals were
considered suitable sites for investigation of current phar-
macopuncture usage. This study investigated current phar-
macopuncture use by assessing the electronic medical
records of all patients visiting 12 KM hospitals and clinics
situated throughout the country from December 17, 2010
to October 2, 2014.
Of included participants, 33,415 were inpatients and
373,755 outpatients, of whom 98.6 and 77.6 % received
pharmacopuncture, respectively. The average number of
pharmacopuncture sessions was 22.8 ± 18.4 times (median:
19) among inpatients, and 8.2 ± 12.3 times (median: 3)
among outpatients. The rate of pharmacopuncture admin-
istration by principle diagnosis codes was highest among
inpatients in M51, S33, M54, S13, and M48, in this order,
and rates varied between 97.2 and 99.3 % for the 10 most
frequent principle diagnosis codes, showing small variance.
Among outpatients, the rate was highest in order of S33,
M51, M54, S13, M50, S93, M17, M47, S83, and M25, and
variance was larger at 73.0 to 91.5 % than that of inpatients
in rate of pharmacopuncture by 10 most frequent principle
diagnosis codes. The reason for this significant divergence
in pharmacopuncture usage rate between inpatients and
outpatients was inferred to be due to difference in severity
of disease. For instance, the rate of pharmacopuncture for
minor diseases such as sprain was lower than that of acu-
puncture in outpatients which suggests that severity of
disease is an important factor in determining use of phar-
macopuncture, i.e. that pharmacopuncture is generally
used more frequently in patients with severe pain to the
aim of resolving such issues. Treatment duration for the
ambulatory department was not analyzed as treatment
period is diverse by patient characteristics and disease se-
verity, and relapse or long-term management is common
in musculoskeletal disease with patients frequently seeking
medical attention up to several months after initial onset,
and resulting in overestimation of period. Meanwhile, fre-
quency of pharmacopuncture use was higher than that of
acupuncture in outpatients, possibly as patients receiving
pharmacopuncture suffered more severe symptoms requir-
ing more treatment to achieve clinical effect. In addition,
considering that the proportion of patients receiving phar-
macopuncture (77.6 %), which is paid entirely out of
pocket and consequently has lower accessibility compared
to acupuncture or electroacupuncture which are covered
by national health insurance, was higher than that of
electroacupuncture (72.8 %), which incurs only $1–2 in
self-payment cost, out of total patients, it may be carefully
inferred that KMDs in Korea regard pharmacopuncture to
be as or more clinically effective than electroacupuncture.
In analysis of pharmacopuncture-related costs in 32,246
inpatients and 229,219 outpatients, average total pharma-
copuncture cost billed per patient during the treatment
period was about $556.24 ± 174.62 among inpatients, and
$149.16 ± 243.85 among outpatients. While direct com-
parison between inpatient and outpatient costs is not pos-
sible as those covered by automobile insurance were
excluded from cost analysis and number of subjects there-
fore differs, but considering the average frequency of treat-
ment in the inpatient/outpatient department, the estimated
average cost per pharmacopuncture session was $23–24 in
inpatients, and $17–18 in outpatients. As these hospitals
leaves decisions on pharmacopuncture cost pending on
overall pharmacopuncture volume and number of acu-
points to physicians within a preset range, it is suggested
that cost in inpatients was generally higher as they pre-
sented more severe cases.
In analysis of pharmacopuncture type, Shinbaro1, bee
venom, Hwangryunhaedok, and Shinbaro2 were shown to
be most frequently used. Shinbaro1 and 2 solutions con-
tain the herbal compound GCSB-5, derived from
Chungpa-jun. The effects of GCSB-5 in anti-inflammation,
neuroprotection, and articular cartilage protection have
been reported in various experimental studies [20–22],
and Shinbaro pharmacopuncture has similarly been
proven to be effective for IDD [14, 23] and arthritis
[24] through clinical research which explains the fre-
quent use in M51 and M17 patients. The safety of
Shinbaro pharmacopuncture has been demonstrated
in single intramuscular dose toxicity tests [25] and re-
peated intramuscular dose toxicity tests [26]. The ef-
fects of bee venom [27] and Hwangryunhaedok [28]
in spinal diseases have also been reported, indicating
that clinically preferred pharmacopuncture types are
mainly evidence-based. It may be further conjectured
that use of evidence-based pharmacopuncture is gain-
ing in popularity amongst KMDs through heightened
credibility drawing from various clinical study results
[4]. It has also been suggested that pharmacopuncture
is used primarily for musculoskeletal disorders given the
fact that the principle diagnosis codes in pharmacopunc-
ture treatment were musculoskeletal. In addition, this
study found that commonly used pharmacopuncture
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solutions were prepared through reflux extraction with
70 % spiritus vinosus, distillation extraction, or isola-
tion and purification. While such methods as low-
temperature, and pressure extraction are also used for
pharmacopuncture solution preparation in Korea [29],
only use of reflux extraction with 70 % spiritus vinosus,
distillation extraction, or isolation and purification was
confirmed in this study as the included KM hospitals
and clinics did not use low-temperature extraction and
pressure extraction.
However, this study holds the following limitations.
Only principle diagnosis codes were included in analyses
and though patients were each assigned one principle
diagnosis code during the study period of 2010 to 2014,
the disease is likely to have progressed or changed over
time in some considering the length of the data extrac-
tion period, and the computerized analysis used in this
study was not equipped to capture such changes. There
is the further limitation that changes in pharmacopunc-
ture type reflecting physician judgment on disease and
symptoms could be not detected, and as a result, the
pharmacopuncture types most commonly used for each
principle diagnosis code could not be established. More-
over, while it was deduced that disease severity may play
an influential role in deciding pharmacopuncture use,
the possibility that some patients may have refused phar-
macopuncture for economic reasons due to noncoverage
cannot be excluded. In addition, this study was unable
to collect data on the volume of pharmacopuncture so-
lution used for treatment or the number of acupoints to
which the treatment was applied. Still, results of a survey
on KMDs employed at the current study sites that 2.9–
5.8 acupoints were chosen for pharmacopuncture in
IDD patients with 1.2–3.9 cc of pharmacopuncture solu-
tion injected at each session may be of reference [12].
Many of the hospitals included in this study were
spine specialty KM hospitals, and the hospitals accord-
ingly treated a large number of IDD (especially M51)
and spinal stenosis patients, which may partially explain
the markedly high frequency of Shinbaro pharmaco-
puncture use. Although this study covered a large num-
ber of KM hospitals and patients, most focused on
spinal disorders and trends may be disparate from gen-
eral KM settings. Nevertheless, KM is mainly used for
musculoskeletal disorders in Korea, and this study is the
first large-scale study on pharmacopuncture use in elec-
tronic medical data from KM hospitals specializing in
musculoskeletal disease treatment and holds significance
as the first report on use of pharmacopuncture for mus-
culoskeletal disorders. The results of this study are ex-
pected to contribute to standardization of treatment
procedures involving pharmacopuncture, future clinical
research design, and inclusion of pharmacopuncture in
Korean national health insurance coverage.
Conclusions
This is the first large-scale analysis on treatment patterns
of pharmacopuncture in KM hospital/clinic patients. We
determined practice patterns regarding pharmacopunc-
ture used for musculoskeletal disease treatment in Korea,
and trends of pharmacopuncture use were shown to de-
pend on severity of disease or symptoms. These results
are expected to contribute to future clinical study design





This study was supported by the Traditional Korean Medicine R&D Program
funded by the Ministry of Health & Welfare through the Korea Health Industry
Development Institute (KHIDI) (HB16C0035). The funder had no role in study
design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Availability of data and materials
The datasets generated during and/or analysed during the current study are
available from the Institutional Review Board of Jaseng Hospital of Korean
medicine for researchers who meet the criteria for access to confidential
patient data.
Authors’ contributions
YJL, JSS, JHL, MRK and IHH drafted the study, and YJL, MRK and IHH wrote the
final manuscript. YJL, JSS, JHL, MRK, KBP, HDL, YML, JWH and IHH contributed to
acquisition of data and the study design and made critical revisions. YJL, KBP
and IHH contributed to analysis and interpretation of data. All of the authors
have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study protocol received approval from the Institutional Review Board of
Jaseng Hospital of Korean Medicine in Korea (KNJSIRB2016-001), and all
investigators adhered to the Helsinki Declaration. Written informed consent
was obtained from patients at all study sites to access and use medical
records for academic means.
Author details
1Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, 858
Eonju-ro, Gangnam-gu, Seoul, Republic of Korea. 2Korea Promotion Institute
for Traditional Medicine Industry, Gyeongsan-si, Gyeongbuk, Republic of
Korea.
Received: 17 March 2016 Accepted: 13 August 2016
References
1. Lee HJ. Introduction to pharmacopuncture and Its Clinic. Seoul: Il-Chung-Sa;
1999.
2. Yin CS, Koh HG. The first documental record on bee venom therapy in
Oriental medicine. J Korean Acupunct Moxibustion Soc. 1998;15(1):143–7.
3. Nam SC. Meridian. Seoul: Hang-Lim-Seo-Won Publications; 1967. p. 4.
4. Kim J, Kang D-I. A descriptive statistical approach to the Korean
pharmacopuncture therapy. J Acupunct Meridian Stud. 2010;3(3):141–9.
5. Kim DH, Cho SJ, Ko JA. Policy improvement plan based on Korean medicine
use. Wonju: Health Insurance Review & Assessment Service; 2015.
Lee et al. BMC Complementary and Alternative Medicine  (2016) 16:292 Page 7 of 8
6. Shen F-Y, Lee MS, Jung S-K. Effectiveness of pharmacopuncture for asthma:
a systematic review and meta-analysis. Evid Based Complement Alternat
Med. 2011;2011:678176.
7. Park Y-A, Kim D-C. Systematic reveiw on complementary and alternative
medicine for breast cancer. J Orient Obstet Gynecol. 2009;22(3):205–22.
8. Committe For Year Book Of Traditional Korean Medicine. 2013 Year book of
traditional Korean medicine. Korea: Committe for Year book of traditional
Korean medicine; 2014.
9. Park OJ, Kim SG, Lee JJ, Lee SM, Kim SJ, Cho NG. The Effect of and Bee
Venom Pharmacopuncture in Treating Lumbar Disc Herniations. Acupunct.
2013;30(5):41–50.
10. Kim E-J, Jang M-K, Yoon E-H, Jung C-Y, Nam D-W, Lee S-D, Kim K-S. Efficacy of
pharmacopuncture using root bark of Ulmus davidiana Planch in patients with
knee osteoarthritis: a double-blind randomized controlled trial. J Acupunct
Meridian Stud. 2010;3(1):16–23.
11. Song H-S. The effect of bee venom acupuncture (BVA) on acute ankle
sprain: A randomized controlled trial and double blinding-pilot study.
J Pharmacopunct. 2005;8(2):11–6.
12. Shin Y-s, Shin J-S, Lee J, Lee YJ, Kim M-r, Ahn Y-j, Park KB, Shin B-C, Lee MS,
Kim J-H: A survey among Korea Medicine doctors (KMDs) in Korea on
patterns of integrative Korean Medicine practice for lumbar intervertebral
disc displacement: Preliminary research for clinical practice guidelines. BMC
Complement Altern Med. 2015;15(1):432.
13. Evidence based Korean medicine clinical practice guideline development
committee for lumbar herniated intervertebral disc. Korean medicine clinical
practice guideline for lumbar herniated intervertebral disc in adults.
Daejeon: Korea Institute of Oriental Medicine; 2014.
14. Jun B, Kim E, Kim D, Kim T, Kim J. Effectiveness of ShinBaro
Pharmacopuncture on Lumbar Spinal Herniated Intervertebral Disc: A
Randomized Controlled Trial. J Korean Soc Chuna Manual Med Spine Nerve.
2011;6(2):109–19.
15. Jang M, Yoon E, Jung C, Kim E, Lee S, Hwang M, Kim K. Review of randomized
controlled trials on Pharmacopuncture treatment for musculoskeletal diseases.
J Korean Acupunct Moxibustion Soc. 2009;26(3):149–63.
16. Lee JH, Kim MJ, Lee JW, Kim MR, Lee IH, Kim EJ. A Study on Standardization
of Pharmacopuncture Using Herbal Medicines Identification Test and HPLC-
DAD. Acupunct. 2015;32(2):1–9.
17. Lee JH, Kim MJ, Lee JW, Kim MR, Lee IH, Kim EJ. Comparison of the
Ingredient Quantities, and Antioxidant and Anti-inflammatory Activities of
Decoction Pharmacopuncture by Preparation Type. Acupunct. 2014;31(4):
45–55.
18. Lee J-H, Shin J-S, Chi E-H, Lee I-H. Comparison of the Amino-Acid Content
in Pharmacopuncture Extracts Taken from a Scorpion’s Body and from Its
Tail. J Pharmacopunct. 2013;16(2):33–40.
19. Cho GY, Han KC, Yoon JY. Stability Test and Quantitative and Qualitative
Analyses of the Amino Acids in Pharmacopuncture Extracted from
Scolopendra subspinipes mutilans. J Pharmacopunct. 2015;18(1):44–55.
20. Chung H-J, Lee H-S, Shin J-S, Lee S-H, Park B-M, Youn Y-S, Lee SK. Modulation
of acute and chronic inflammatory processes by a traditional medicine
preparation GCSB-5 both in vitro and in vivo animal models. J Ethnopharmacol.
2010;130(3):450–9.
21. Kim T-H, Yoon S-J, Lee W-C, Kim J-K, Shin J, Lee S, Lee S-M. Protective
effect of GCSB-5, an herbal preparation, against peripheral nerve injury
in rats. J Ethnopharmacol. 2011;136(2):297–304.
22. Kim J-K, Park S-W, Kang J-W, Kim Y-J, Lee SY, Shin J, Lee S, Lee S-M: Effect of
GCSB-5, a herbal formulation, on monosodium iodoacetate-induced
osteoarthritis in rats. Evid Based Complement Alternat Med. 2012;2012:
730907.
23. Park JJ, Shin J, Choi Y, Youn Y, Lee S, Kwon S-R, Lee H, Kang M-H, Ha I-H,
Shin I. Integrative package for low back pain with leg pain in Korea: a
prospective cohort study. Complement Ther Med. 2010;18(2):78–86.
24. Park Y-G, Ha C-W, Han C-D, Bin S-I, Kim H-C, Jung Y-B, Lim H-C. A prospective,
randomized, double-blind, multicenter comparative study on the safety and
efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment
of osteoarthritis of knee joint. J Ethnopharmacol. 2013;149(3):816–24.
25. Lee JH, Chung HJ, Lee IH, Lee JW, Kim EJ, Kim MJ. Study on Single-dose
Intramuscular Toxicity of Shinbaro Pharmacopuncture in Sprague–Dawley
(SD) Rats and Beagle Dogs. J Korean Acad Rehabil Med. 2015;25(3):1–9.
26. Lee JH, Ha IH, Kim MR, Kim MJ, Lee JW, Lee IH, Chung HJ, Kim EJ. Multiple-
dose Intramuscular Toxicity Study of Shinbaro Pharmacopuncture in
SpragueDawley Rats over a 4-week period. Acupunct. 2015;32(4):77–89.
27. Shin B-C, Kong JC, Park T-Y, Yang C-Y, Kang K-W, Choi S-m. Bee venom
acupuncture for chronic low back pain: A randomised, sham-controlled,
triple-blind clinical trial. Eur J Intern Med. 2012;4(3):e271–80.
28. Park SH, Ro HR, Kim TH, Park JY. The comparative study on the effect of bee
venom pharmacopuncture treatment and Hwangryun pharmacopuncture
treatment of cervical disc herniation. Acupunct. 2013;30(3):117–24.
29. Kwon K, Kim S, Kim C. Pharmacopuncturology. Seoul, Korea: Elsevier; 2011.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lee et al. BMC Complementary and Alternative Medicine  (2016) 16:292 Page 8 of 8
